Navigation Links
Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
Date:6/19/2013

ch (CDER)

(3) 2011 National Academy of Sciences. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education and Research, 2010 Decision Resources, and Harstall, C. How prevalent is chronic pain? Pain Clinical Updates X, 1—4 (2003).

(4) IMS, NSP, NPA and Defined Health 2010 Estimates.

(5) Melnikova, I, Pain Market, Nature Reviews Drug Discovery, Volume 9, 589-90 (August 2010).

(6) Morbidity and Mortality Weekly Report (MMWR), Emergency Department Visits Involving Nonmedical Use of Selected Prescription Drugs --- United States, 2004—2008, 59(23);705-709 (June 2010).


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
2. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
3. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
5. Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
6. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
7. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
8. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
9. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: ... the Office of Fair Trading (OFT) approval condition to the announced ... (NASDAQ: VPHM).   As a result of the waiver, ... expects to complete the tender offer on January 24, 2014 following ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and ... be able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of the ... steadfastly remains one of the most litigious industry ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... Mo., Feb. 14, 2011 K-V Pharmaceutical Company (NYSE: ... into a definitive agreement with a group of institutional ... from a private placement of 9,950,000 shares of its ... Company will use $20 million of the proceeds from ...
... commonly prescribed osteoporosis drug is associated with a slightly ... osteonecrosis of the jaw; nonetheless the risk remains extremely ... Journal of Dental Research, the official journal of ... the findings are provocative, study authors say they should ...
Cached Medicine Technology:K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 2K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 3K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 4K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 5K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 6K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 7K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 8K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 9K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 10K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 11K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 12K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock 13Commonly Prescribed Osteoporosis Drug Associated with Very Low Risk of Serious Jaw Disease 2Commonly Prescribed Osteoporosis Drug Associated with Very Low Risk of Serious Jaw Disease 3Commonly Prescribed Osteoporosis Drug Associated with Very Low Risk of Serious Jaw Disease 4
(Date:7/10/2014)... News) -- Adults with dyslexia are more likely to ... teenagers than people who don,t have the learning disorder, ... affects up to 10 percent of people, causes problems ... of adults with this condition said they suffered physical ... those without dyslexia. "Even after accounting for age, ...
(Date:7/10/2014)... Kristen Fischer HealthDay Reporter ... may help ease the hot flashes that often accompany menopause, ... more than 50 percent of menopausal women, said Dr. Taraneh ... science at the Icahn School of Medicine at Mount Sinai ... experience more than 10 hot flashes a day, and she ...
(Date:7/10/2014)... Dennis Thompson HealthDay Reporter ... the Twitter wars that break out regularly between outspoken celebrities ... for your own relationship, a new study suggests. High ... couple, even if the couple is in a long-term relationship, ... users. In turn, that friction can lead to cheating ...
(Date:7/10/2014)... that the "Mississippi Baby," believed to have been functionally ... detectable levels of the virus, the Elizabeth Glaser Pediatric ... remains hopeful that the scientific breakthrough that allowed the ... two years will continue to help researchers understand how ... , "Although we had high hopes that the child ...
(Date:7/10/2014)... than 200 experts on aggression, who research issues ranging ... the 21st World Meeting of the International Society for ... July 15-19. , Georgia State University is hosting the ... on alternating continents. , "We are excited to be ... countries, which will help produce fresh ideas about the ...
Breaking Medicine News(10 mins):Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3Health News:Despite setback, 'Mississippi Baby' represents significant breakthrough in effort to end AIDS 2Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3
... OXFORD, England, July 13 International medical,communications ... the Year at the Communique Awards in London ... by an independent panel of,communications experts, who assess ... for healthcare clients, along with business strategy,client retention, ...
... Gentiva Health Services, Inc. (Nasdaq: GTIV ), a ... scheduled a conference call and web cast on Thursday, July 30, 2009, ... ended June 28, 2009. Gentiva plans to issue its financial news release ... , The conference call is open to investment analysts ...
... July 13 Sunesis Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of new oncology therapeutics for the treatment ... has received a $1.5 million milestone payment from Biogen ... of a Raf kinase inhibitor development candidate for the ...
... New data pooled from four large, "real world" ... VIII (rFVIII-FS) reduced bleeding and provided data regarding ... mild-to-severe hemophilia A. Additionally, rates of inhibitor formation ... untreated patients. The data were presented at the ...
... , SUNNYVALE, Calif., July 13 Cepheid (Nasdaq: CPHD ... & Drug Administration (FDA) to market its Xpert(R) C. difficile ... of the bacterium that causes Clostridium difficile infection (CDI). ... for CDI to deliver both rapid turnaround and a high degree ...
... , PORT WASHINGTON, N.Y., July 13 ... of the American Medical Association has granted a CPT Category ... (TM) (MCG) system. MCG is the World,s first Internet based, ... for interactive online diagnosis. The MCG is intended as ...
Cached Medicine News:Health News:Gentiva(R) Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday, July 30, 2009 2Health News:Gentiva(R) Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday, July 30, 2009 3Health News:Gentiva(R) Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday, July 30, 2009 4Health News:Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec 2Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 2Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 3Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 4Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 5Health News:Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection 2Health News:Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection 3Health News:Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection 4Health News:Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection 5Health News:AMA Grants New Category III CPT Code to Premier Heart's Multifunction CardioGram(TM) (MCG) 2
... provided by a cool-running, energy efficient LEDs ... you need to see without affecting the ... they are maintenance free so you'll never ... Phoroptor comes with a limited lifetime warranty, ...
... The Reichert CT200 Tonometer ... the XCEL 250 and XCEL ... also compatible with other Zeiss-style ... mounted on the top of ...
10 (mm) smooth platform; Serrated handle in stainless steel....
Compatible with the Volcano Therapeutics Trak Back II Disposable Catheter Pullback Device,and the Volcano Therapeutics In-Vision Imaging System....
Medicine Products: